Establishing Unrestricted Trading Line

TYRATECH, INC.

("TyraTech" or "the Company")

Establishing Unrestricted Trading Line

TyraTech, Inc. (AIM: TYR), a leading independent novel pesticide company for human, animal and environmental health, is pleased to announce that the Company has started the process of establishing a second trading facility (AIM: TYRU) to enable certain eligible Common Shares to have US trading restrictions removed. Removal of trading restrictions allows the shares to be:

·; transferred to a new unrestricted trading line (AIM: TYRU);

·; settled, by means of Depositary Interests, through the CREST electronic settlement system; and

·; sold in the US if the holders elect.

The Company expects that trading on this second, unrestricted line will begin around the end of August 2010.

TyraTech currently has a total of 47,193,022 Common Shares admitted to AIM and trading under the symbol TYR in a restricted manner as permitted by Regulation S of the U.S. Securities Act of 1933 (the 'Securities Act').  Common Shares that have been in issue for more than one year and are not held by 'affiliates' generally qualify for characterisation as 'Unrestricted Common Shares' under an exemption provided by Rule 144(k) of the Securities Act. All Unrestricted Common Shares will be eligible for migration to, and trading on, the unrestricted TYRU line once the trading facility is formally in place. All shares not meeting the definition of Unrestricted Common Shares will continue to trade in a restricted manner under the TYR line. There is no difference between the Common Shares trading in the restricted line and those trading in the unrestricted line, but the TYRU line will serve to evidence the absence of restrictions on trading otherwise imposed by the Securities Act that will enable electronic settlement if a holder so desires.

The Directors of TyraTech believe that creating a second line to enable its unrestricted Common Shares to trade and settle electronically via the CREST system will make investing in the Company more attractive to many investors and could improve liquidity under the unrestricted trading symbol.

In the coming weeks, the Company will announce the date when trading on the TYRU line will commence and the CREST settlement system will be enabled for these shares. The Company has sent letters to eligible shareholders with instructions for migrating their shares to the TYRU line. To participate, holders of eligible shares must deliver their current restricted share certificate to the Company's transfer agent (Computershare - Channel Islands) together with the Letter of Transmittal provided to them by August 13 2010 and will receive an unrestricted certificate in return.

Copies of the letter to shareholders and the Letter of Transmittal are available at www.tyratech.com.

For further information please contact:

TyraTech Inc.

Keith Bigsby, Chief Financial Officer +1 (321) 409 7714

www.tyratech.com

Nomura Code Securities

Richard Potts/Christopher Golden +44 (0)20 7776 1200

www.nomuracode.com

Buchanan Communications

Lisa Baderoon/ Catherine Breen +44 (0) 20 7466 5000

www.buchanan.uk.com

About TyraTech

TyraTech was formed in 2004 to develop and commercialise products for the control of invertebrate pests and pathogens using the Company's proprietary technology. TyraTech, which already has products on the market, is positioned for human health, animal health and pesticide market opportunities which total over $32 billion globally. TyraTech's technology provides the Company with a wide variety of product and business opportunities in many markets and geographic regions. The differentiating feature of these products is the potential to have a combined level of potency and safety that other invertebrate control products are unable to offer. TyraTech's platform brings many of the principles of drug discovery and development to the fields of insecticides and parasiticides. By targeting specific chemoreceptors that are found in invertebrates but not in humans and animals, TyraTech can produce products that use natural plant derived compounds targeting these receptors.

TyraTech is actively developing selected proprietary active ingredients which can then be used for various products across a wide variety of market segments, either by development partners or by TyraTech itself. TyraTech already has products or partnerships in the areas of professional and horticultural insect control, and for an insect/mosquito repellent. TyraTech also has an innovative partnership with Kraft to use its natural oils to develop functional foods for improving the health of the more than 2 billion people worldwide subject to intestinal parasitic infections.